| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
41,954,000 |
| Market
Cap: |
1.99(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$12.375 - $50.91 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1162 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile AnaptysBio is a clinical stage biotechnology company developing immunology therapeutic product candidates focused on immune control mechanisms applicable to inflammation and immuno-oncology indications. Co.'s wholly-owned antibody programs include: imsidolimab, which inhibits the interleukin-36 receptor and is being developed for the treatment of multiple dermatological inflammatory diseases; rosnilimab, which is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling via rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, which is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
359,070 |
| Total Buy Value |
$0 |
$0 |
$0 |
$11,099,621 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
146,280 |
164,751 |
191,706 |
406,051 |
| Total Sell Value |
$6,715,086 |
$7,154,760 |
$7,792,491 |
$13,318,831 |
| Total People Sold |
6 |
7 |
8 |
8 |
| Total Sell Transactions |
21 |
23 |
26 |
42 |
| End Date |
2025-10-26 |
2025-07-25 |
2025-01-24 |
2024-01-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Marquet Magda |
|
– • – |
2026-01-15 |
4 |
S |
$48.12 |
$530,531 |
D/D |
(11,000) |
9,930 |
|
-2% |
|
| Marquet Magda |
|
– • – |
2026-01-15 |
4 |
OE |
$26.11 |
$287,210 |
D/D |
11,000 |
20,930 |
|
- |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2026-01-08 |
4 |
S |
$44.71 |
$112,446 |
D/D |
(2,515) |
21,852 |
|
-8% |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2026-01-08 |
4 |
S |
$44.71 |
$98,809 |
D/D |
(2,210) |
12,835 |
|
-8% |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2026-01-08 |
4 |
S |
$44.71 |
$163,192 |
D/D |
(3,650) |
42,088 |
|
-8% |
|
| Faga Daniel |
President, CEO |
• • – |
2026-01-08 |
4 |
S |
$44.71 |
$638,504 |
D/D |
(14,281) |
479,344 |
|
-8% |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2026-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,700 |
24,367 |
|
- |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2026-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,888 |
15,045 |
|
- |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2026-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,525 |
45,738 |
|
- |
|
| Faga Daniel |
President, CEO |
• • – |
2026-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,838 |
493,625 |
|
- |
|
| Faga Daniel |
President, CEO |
• • – |
2026-01-07 |
4 |
S |
$45.11 |
$415,102 |
D/D |
(9,202) |
466,787 |
|
-5% |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2026-01-07 |
4 |
S |
$45.11 |
$100,821 |
D/D |
(2,235) |
37,213 |
|
-5% |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2026-01-07 |
4 |
AS |
$45.11 |
$439,200 |
D/D |
(9,639) |
9,157 |
|
5% |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2026-01-07 |
4 |
S |
$45.11 |
$86,070 |
D/D |
(1,908) |
17,667 |
|
-5% |
|
| Faga Daniel |
President, CEO |
• • – |
2026-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,850 |
475,989 |
|
- |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2026-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,145 |
39,448 |
|
- |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2026-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,545 |
18,796 |
|
- |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2026-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,245 |
19,575 |
|
- |
|
| Faga Daniel |
President, CEO |
• • – |
2026-01-05 |
4 |
S |
$43.26 |
$662,267 |
D/D |
(15,309) |
458,139 |
|
-10% |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2026-01-05 |
4 |
S |
$43.26 |
$182,514 |
D/D |
(4,219) |
33,303 |
|
-10% |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2026-01-05 |
4 |
S |
$43.26 |
$145,483 |
D/D |
(3,363) |
14,330 |
|
-10% |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2026-01-05 |
4 |
S |
$43.26 |
$129,045 |
D/D |
(2,983) |
13,251 |
|
-10% |
|
| Faga Daniel |
President, CEO |
• • – |
2026-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,677 |
473,448 |
|
- |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2026-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,555 |
37,522 |
|
- |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2026-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,292 |
17,693 |
|
- |
|
239 Records found
|
|
Page 1 of 10 |
|
|
0.21 (0.44%) 
